Have a feature idea you'd love to see implemented?
Let us know!
PRTA Prothena Corp Public Ltd Co
Price (delayed)
$14.44
Market cap
$777M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.46
Enterprise value
$269.23M
Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating
Highlights
Prothena's debt has increased by 7% YoY but it has decreased by 5% from the previous quarter
The net income has plunged by 159% from the previous quarter and by 80% YoY
The company's EPS has shrunk by 159% QoQ and by 82% YoY
Key stats
What are the main financial stats of PRTA
Market
Valuations
Earnings
Shares outstanding
53.81M
Market cap
$777M
Enterprise value
$269.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.45
Price to sales (P/S)
5.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.02
Revenue
$133.35M
EBIT
-$140.05M
EBITDA
-$134.84M
Free cash flow
-$155.08M
Per share
Balance sheet
Liquidity
EPS
-$2.46
Free cash flow per share
-$2.88
Book value per share
$9.94
Revenue per share
$2.48
TBVPS
$11.07
Total assets
$595.25M
Total liabilities
$60.89M
Debt
$11.49M
Equity
$534.36M
Working capital
$488.56M
Debt to equity
0.02
Current ratio
11.52
Quick ratio
11.19
Net debt/EBITDA
3.77
Margins
Efficiency
Dividend
EBITDA margin
-101.1%
Gross margin
100%
Net margin
-98.9%
Operating margin
-126.1%
Return on assets
-20.6%
Return on equity
-24.2%
Return on invested capital
-342.5%
Return on capital employed
-25.5%
Return on sales
-105%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRTA stock price
How has the Prothena stock price performed over time
Intraday
0.28%
1 week
-10.31%
1 month
-12.48%
1 year
-55.31%
YTD
-60.26%
QTD
-13.69%
Financial performance
How have Prothena's revenue and profit performed over time
Revenue
$133.35M
Gross profit
$133.35M
Operating income
-$168.18M
Net income
-$131.83M
Gross margin
100%
Net margin
-98.9%
The operating margin has dropped by 200% since the previous quarter and by 58% year-on-year
The net income has plunged by 159% from the previous quarter and by 80% YoY
Prothena's net margin has plunged by 91% YoY
Prothena's operating income has shrunk by 84% QoQ and by 49% YoY
Growth
What is Prothena's growth rate over time
Valuation
What is Prothena stock price valuation
P/E
N/A
P/B
1.45
P/S
5.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.02
The company's EPS has shrunk by 159% QoQ and by 82% YoY
PRTA's price to book (P/B) is 62% lower than its 5-year quarterly average of 3.8 and 40% lower than its last 4 quarters average of 2.4
The company's equity fell by 13% YoY and by 8% QoQ
PRTA's price to sales (P/S) is 98% lower than its 5-year quarterly average of 248.6 and 52% lower than its last 4 quarters average of 12.0
Prothena's revenue has decreased by 39% from the previous quarter and by 5% YoY
Efficiency
How efficient is Prothena business performance
Prothena's return on assets has shrunk by 175% QoQ and by 108% YoY
The ROE has plunged by 169% from the previous quarter and by 100% YoY
The ROIC has plunged by 116% from the previous quarter but it has soared by 61% YoY
The company's return on sales has shrunk by 71% YoY
Dividends
What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRTA.
Financial health
How did Prothena financials performed over time
The total liabilities has dropped by 53% year-on-year and by 4.3% since the previous quarter
The total assets has decreased by 20% YoY and by 8% from the previous quarter
Prothena's debt is 98% less than its equity
The company's equity fell by 13% YoY and by 8% QoQ
Prothena's debt has increased by 7% YoY but it has decreased by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.